Uncategorized

Perfuse Therapeutics announced that the US Food and Drug Administration has cleared the Investigational New Drug application for a Phase 1/2a clinical study of PER-001 Intravitreal Implant in patients with glaucoma.

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, receives subscription commitment subject to certain conditions, of bonds to an aggregated amount of EUR 40 million.

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that its Annual Report for 2022 has been published.

Dr. Hamid Abbasi, a renowned spine surgeon and innovator, has successfully performed the first Inspired Spine Trans-Kambin Oblique Lateral Lumbar Interbody Fusion with Arrow Cage in South America.

RELIEF THERAPEUTICS Holding SA announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities.

While financier Carl Icahn and regulators in the U.S. and Europe want DNA-sequencing company Illumina to divest liquid biopsy company Grail, Illumina’s board won’t budge. Analysts say they may be waiting for the best moment.

With an inaugural $350 million fund, Cure Ventures launched Tuesday to support early-stage companies with cutting-edge curative technologies and help them de-risk their science

More trouble for Philips’ Respironics business as the company flags a problem with ventilators that could lead to under-delivery of oxygen due to inaccurate readings.

Two hospital groups are arguing that federal staffing mandates are a “one-size-fits-all” approach to the labor crisis and that issuing mandates could reduce capacity by forcing nursing homes to shut their doors.

The state attorney general’s office has cautioned against a quick merger since the deal was first announced in November.